Shopping Cart 0
Cart Subtotal
USD 0

Ascletis Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Ascletis Inc (Ascletis) is a healthcare company that provides therapeutics for cancer and infectious diseases. The company offers discovery, demonstration of global partnering, clinical proof-of-concept, and research and development services of novel therapeutics for life-threatening diseases. Its research and development services comprise product indication, lead development, pre clinical studies and phase development services. Ascletis's development pipelines comprise danoprevirs, PPI, ALN-VSP and others. The company offers discovery and development of important therapeutics with both small molecule and biologics approaches. It provides in-licensing, late-stage clinical development, and commercialization services. The company has its presence in the US and China. Ascletis is headquartered in Chapel Hill, North Carolina, the US.

Ascletis Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Ascletis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Ascletis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Ascletis Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Ascletis Pharma Raises USD100.7 Million in Series B Financing 10

Ascletis Raises USD35 Million in Venture Financing 11

Ascletis Raises US$50 Million In First Tranche Of Series A Financing 12

Partnerships 13

Roche Enters Into Agreement With Ascletis To Develop HCV Drug Danoprevir 13

Ascletis Enters Into Agreement With Minsheng Pharma For R&D 14

Licensing Agreements 14

Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 14

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 15

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 16

Equity Offering 17

Ascletis Raises USD20 Million in Private Placement of Shares 17

Ascletis Inc-Key Competitors 19

Key Employees 20

Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Appendix 22

Methodology 22

About GlobalData 22

Contact Us 22

Disclaimer 22


List Of Figure

List of Figures

Ascletis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Ascletis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List Of Table

List of Tables

Ascletis Inc, Pharmaceuticals & Healthcare, Key Facts 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Ascletis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Ascletis Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Ascletis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Ascletis Pharma Raises USD100.7 Million in Series B Financing 10

Ascletis Raises USD35 Million in Venture Financing 11

Ascletis Raises US$50 Million In First Tranche Of Series A Financing 12

Roche Enters Into Agreement With Ascletis To Develop HCV Drug Danoprevir 13

Ascletis Enters Into Agreement With Minsheng Pharma For R&D 14

Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 14

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 15

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 16

Ascletis Raises USD20 Million in Private Placement of Shares 17

Ascletis Inc, Key Competitors 19

Ascletis Inc, Key Employees 20

Ascletis Inc, Other Locations 21

Ascletis Inc, Subsidiaries 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Ascletis Inc (Ascletis) is a healthcare company that provides therapeutics for cancer and infectious diseases. The company offers discovery, demonstration of global partnering, clinical proof-of-concept, and research and development services of novel therapeutics for life-threatening diseases. Its research and development services comprise product indication, lead development, pre clinical studies and phase development services. Ascletis's development pipelines comprise danoprevirs, PPI, ALN-VSP and others. The company offers discovery and development of important therapeutics with both small molecule and biologics approaches. It provides in-licensing, late-stage clinical development, and commercialization services. The company has its presence in the US and China. Ascletis is headquartered in Chapel Hill, North Carolina, the US.

Ascletis Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Ascletis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Ascletis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Ascletis Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Ascletis Pharma Raises USD100.7 Million in Series B Financing 10

Ascletis Raises USD35 Million in Venture Financing 11

Ascletis Raises US$50 Million In First Tranche Of Series A Financing 12

Partnerships 13

Roche Enters Into Agreement With Ascletis To Develop HCV Drug Danoprevir 13

Ascletis Enters Into Agreement With Minsheng Pharma For R&D 14

Licensing Agreements 14

Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 14

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 15

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 16

Equity Offering 17

Ascletis Raises USD20 Million in Private Placement of Shares 17

Ascletis Inc-Key Competitors 19

Key Employees 20

Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Appendix 22

Methodology 22

About GlobalData 22

Contact Us 22

Disclaimer 22


List Of Figure

List of Figures

Ascletis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Ascletis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List Of Table

List of Tables

Ascletis Inc, Pharmaceuticals & Healthcare, Key Facts 1

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Ascletis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Ascletis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Ascletis Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Ascletis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Ascletis Pharma Raises USD100.7 Million in Series B Financing 10

Ascletis Raises USD35 Million in Venture Financing 11

Ascletis Raises US$50 Million In First Tranche Of Series A Financing 12

Roche Enters Into Agreement With Ascletis To Develop HCV Drug Danoprevir 13

Ascletis Enters Into Agreement With Minsheng Pharma For R&D 14

Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 14

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 15

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 16

Ascletis Raises USD20 Million in Private Placement of Shares 17

Ascletis Inc, Key Competitors 19

Ascletis Inc, Key Employees 20

Ascletis Inc, Other Locations 21

Ascletis Inc, Subsidiaries 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS